These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 36848533)

  • 41. Central Nervous System Prophylaxis Strategies in Diffuse Large B Cell Lymphoma.
    Kansara R
    Curr Treat Options Oncol; 2018 Sep; 19(11):52. PubMed ID: 30203318
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Integrin alpha 10, CD44, PTEN, cadherin-11 and lactoferrin expressions are potential biomarkers for selecting patients in need of central nervous system prophylaxis in diffuse large B-cell lymphoma.
    Lemma SA; Kuusisto M; Haapasaari KM; Sormunen R; Lehtinen T; Klaavuniemi T; Eray M; Jantunen E; Soini Y; Vasala K; Böhm J; Salokorpi N; Koivunen P; Karihtala P; Vuoristo J; Turpeenniemi-Hujanen T; Kuittinen O
    Carcinogenesis; 2017 Aug; 38(8):812-820. PubMed ID: 28854563
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A Rare Presentation of Primary Central Nervous System Lymphoma in an Immunocompetent Patient.
    DeRon N; Ahmed M; Lopez D; Alobaidi A
    Cureus; 2022 Apr; 14(4):e23858. PubMed ID: 35530884
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Inflammatory brain lesions preceding primary central nervous system lymphoma: a case report and genetic analysis.
    XiaoHong Z; Shuo Y; GeHong D; AnChao Y; Ce W; YunYun D; Can W; SiJie H; Feng C; WenBin L
    Neurol Sci; 2023 May; 44(5):1555-1561. PubMed ID: 36599976
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical and histological features of primary testicular diffuse large B-cell lymphoma: a single center experience in China.
    Zhou D; Bao C; Ye X; Zhu L; Zhu J; Li L; Zhu M; Yang X; Zheng Y; Huang X; Xie M; Xie W
    Oncotarget; 2017 Dec; 8(68):112384-112389. PubMed ID: 29348832
    [TBL] [Abstract][Full Text] [Related]  

  • 46. (11)C-methionine PET/CT and MRI of primary central nervous system diffuse large B-cell lymphoma before and after high-dose methotrexate.
    Jang SJ; Lee KH; Lee JY; Choi JY; Kim BT; Kim SJ; Kim WS
    Clin Nucl Med; 2012 Oct; 37(10):e241-4. PubMed ID: 22955084
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
    Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ
    Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cutaneous metastasis of primary diffuse large B-cell lymphoma of the central nervous system developing 4 years after complete remission: Diagnosis confirmed by comparison of clones.
    Patel BM; Moesch J; Karunamurthy A; Puleio DV; Drappatz J; Akilov OE; Kazlouskaya V
    J Cutan Pathol; 2022 Jan; 49(1):90-94. PubMed ID: 34498750
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Clinical manifestation and treatment of extranodal diffuse large B-cell lymphoma].
    Tomita N
    Rinsho Ketsueki; 2016; 57(10):1991-1999. PubMed ID: 27725597
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Systems biology of primary CNS lymphoma: from genetic aberrations to modeling in mice.
    Deckert M; Montesinos-Rongen M; Brunn A; Siebert R
    Acta Neuropathol; 2014 Feb; 127(2):175-88. PubMed ID: 24240734
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab.
    Tai WM; Chung J; Tang PL; Koo YX; Hou X; Tay KW; Quek R; Tao M; Lim ST
    Ann Hematol; 2011 Jul; 90(7):809-18. PubMed ID: 21229246
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Primary central nervous system lymphoma--a report of 32 cases with literature review].
    Yi JQ; Lin TY; He YJ; Huang HQ; Xia ZJ; Xia YF; Xu RH; Guo Y; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):476-80. PubMed ID: 16613684
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clonal evolution in diffuse large B-cell lymphoma with central nervous system recurrence.
    Magnes T; Wagner S; Thorner AR; Neureiter D; Klieser E; Rinnerthaler G; Weiss L; Huemer F; Zaborsky N; Steiner M; Weis S; Greil R; Egle A; Melchardt T
    ESMO Open; 2021 Feb; 6(1):100012. PubMed ID: 33399078
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical Effect of CD25 on the Prognosis of Diffuse Large B Cell Lymphoma with Secondary Central Nervous System Relapse.
    Oka S; Ono K; Nohgawa M
    Pathol Oncol Res; 2020 Jul; 26(3):1843-1850. PubMed ID: 31768966
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prophylaxis strategies containing high dose intravenous methotrexate on preventing CNS relapse for patients with diffuse large B-cell lymphoma at intermediate to high risk: A study based on 12 cohorts in the rituximab era.
    Zhang N; Xu D; Liu B; Shi X; Xie X; Wang Z
    Int Immunopharmacol; 2022 Dec; 113(Pt A):109299. PubMed ID: 36252471
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Primary central nervous system lymphoma in Korea: comparison of B- and T-cell lymphomas.
    Choi JS; Nam DH; Ko YH; Seo JW; Choi YL; Suh YL; Ree HJ
    Am J Surg Pathol; 2003 Jul; 27(7):919-28. PubMed ID: 12826884
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Analysis of Key Factors Associated with Response to Salvage High-Dose Methotrexate Rechallenge in Primary Central Nervous System Lymphoma with First Relapse.
    Du P; Chen H; Shen L; Liu X; Wu X; Chen L; Cao A; Geng D
    Curr Oncol; 2022 Sep; 29(9):6642-6656. PubMed ID: 36135091
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Similar chemokine receptor profiles in lymphomas with central nervous system involvement - possible biomarkers for patient selection for central nervous system prophylaxis, a retrospective study.
    Lemma SA; Pasanen AK; Haapasaari KM; Sippola A; Sormunen R; Soini Y; Jantunen E; Koivunen P; Salokorpi N; Bloigu R; Turpeenniemi-Hujanen T; Kuittinen O
    Eur J Haematol; 2016 May; 96(5):492-501. PubMed ID: 26153511
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Primary central nervous system lymphoma: advances in its pathogenesis, molecular markers and targeted therapies.
    Hernández-Verdin I; Morales-Martínez A; Hoang-Xuan K; Alentorn A
    Curr Opin Neurol; 2022 Dec; 35(6):779-786. PubMed ID: 36367044
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The molecular hallmarks of primary and secondary vitreoretinal lymphoma.
    Bonzheim I; Sander P; Salmerón-Villalobos J; Süsskind D; Szurman P; Gekeler F; Spitzer MS; Steinhilber J; Kohler E; Büssgen M; Schittenhelm J; Salaverria I; Campo E; Coupland SE; Quintanilla-Martinez L; Fend F
    Blood Adv; 2022 Mar; 6(5):1598-1607. PubMed ID: 34448823
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.